The obesity drug company could be valued at $200 billion in these years

1 May, 2023: The burgeoning weight-loss pharmaceutical industry, whetting investors’ appetites with its pledge to combat global obesity rates, could be worth nearly $200 billion within the upcoming decade, according to Barclays Bank.

The obesity of “the story of this decade,” Barclays’ head of European pharmaceuticals equity research stated that, based on investor feedback, the bank’s last valuation estimate may have been overly conservative.

In a research note released in the previous week, Barclays said the global obesity therapeutic market could be valued at $100 billion by around 2030. Therefore, Emily Field elevated that estimate Wednesday.

“Immuno-oncology was the story of the previous decade. It feels such as obesity is the story of this year,” Field said.

“We think it can acquire a $100 billion market” in the next ten years. “Maybe it could be even making it more if this keeps going, and we see higher penetration.”

Weight-loss medicines have become a hot topic as public health authorities and pharmaceutical firms seek solutions to the growing obesity epidemic.

According to the World Health Organization, international obesity rates have tripled over the past decade. Currently, 1 billion people are clinically obese, of whom around 650 million are grownups, 340 million are adolescents, and 39 million are small.

Pharmaceutical creators Novo Nordisk and Eli Lily are those grabbing attention for tackling waistlines with weight-loss drugs, including Wegovy, Ozempic and Mounjaro.

Eli Lily said Thursday that it would be applying for regulatory approval for Mounjaro after an extensive trial showed that it supported overweight people with type 2 diabetes to lose almost 16% of their body weight.